James B Breitmeyer Oncternal Therapeutics, Inc. (ONCT) insider trading activity

James B Breitmeyer is Chief Executive Officer of Oncternal Therapeutics, Inc.. Currently has a direct ownership of 443,034 shares of ONCT, which is worth approximately $234,808. The most recent transaction as insider was on Jan 03, 2024, when has been sold 50,955 shares (Common Stock) at a price of $0.5 per share, resulting in proceeds of $25,477. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 443K

0% 3M change

10.32% 12M change

Total Value Held $234,808

JAMES B BREITMEYER Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 03 2024	SELL Payment of exercise price or tax liability	$25,477 $0.5 p/Share	50,955 Reduced 10.32%	443,034 Common Stock
Jul 03 2023	SELL Payment of exercise price or tax liability	$17,277 $0.36 p/Share	47,992 Reduced 8.85%	493,989 Common Stock
Jan 03 2023	SELL Payment of exercise price or tax liability	$28,348 $1.02 p/Share	27,793 Reduced 4.88%	541,981 Common Stock
Jul 28 2022	BUY Grant, award, or other acquisition	-	185,625 Added 24.57%	569,774 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	128,557 Added 25.07%	384,149 Common Stock

Also insider at

OTIC

OTONOMY, INC. Healthcare

Director

ZGNX

ZOGENIX, INC.

Director

JBB